A Novel EGFRC797 Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture-Based Next-Generation Sequencing Assay

Journal of Thoracic Oncology

Volumn 11, Issue 9, 2016, Pages e105-e107

  Menon, Roopika ^a   Müller, Judith ^a   Schneider, Petra ^a   Lakis, Sotirios ^a   Thress, Kenneth ^b   Wolf, Jürgen ^c   Heukamp, Lukas ^a   Heuckmann, Johannes M ^a   Griesinger, Frank ^d  

^a NEO New Oncology GmbH   (Germany)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d PIUS HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; HEAT SHOCK PROTEIN 90 INHIBITOR; OSIMERTINIB; PEMETREXED; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PIPERAZINE DERIVATIVE;

ADULT; ARTICLE; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; CENTRAL NERVOUS SYSTEM METASTASIS; COMPASSIONATE USE; COPY NUMBER VARIATION; DIAGNOSTIC ACCURACY; EXON; GENE FREQUENCY; GENE FUSION; GENETIC RESISTANCE; GENETIC VARIABILITY; HUMAN; INDEL MUTATION; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG NODULE; MAINTENANCE THERAPY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MYELOID LEUKEMIA; NEXT GENERATION SEQUENCING; PLEURA BIOPSY; PLEURA EFFUSION; PLEURODESIS; POINT MUTATION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT RESPONSE; VIDEO ASSISTED THORACOSCOPIC SURGERY; VIRUS ONCOGENE; ADENOCARCINOMA; BIOPSY; CHEMICALLY INDUCED; DRUG RESISTANCE; GENETICS; HIGH THROUGHPUT SEQUENCING; LUNG TUMOR; MUTATION; PATHOLOGY; PLEURA TUMOR; PROCEDURES; SECONDARY;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BIOPSY; DRUG RESISTANCE, NEOPLASM; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PIPERAZINES; PLEURAL NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84987845565     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.04.005     Document Type: Article

References (5)

1. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352:786-792.
2. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3: 75ra26.
3. Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372:1689-1699.
4. Barlesi F, Besse B, Chu Q, et al. Phase II activity of the HSP90 inhibitor AUY922 in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC). Paper presented at: 15th World Conference on Lung Cancer. October 27-30, 2013. Sydney, Australia.
5. Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21:560-562.